These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 16085553)
1. Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Kamble R; Wilson CS; Fassas A; Desikan R; Siegel DS; Tricot G; Anderson P; Sawyer J; Anaissie E; Barlogie B Leuk Lymphoma; 2005 Aug; 46(8):1137-42. PubMed ID: 16085553 [TBL] [Abstract][Full Text] [Related]
2. Myelomatous pleural effusion: a case series in a single institution and literature review. Cho YU; Chi HS; Park CJ; Jang S; Seo EJ; Suh C Korean J Lab Med; 2011 Oct; 31(4):225-30. PubMed ID: 22016674 [TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma with myelomatous pleural effusion: a case report and review of the literature. Kim YJ; Kim SJ; Min K; Kim HY; Kim HJ; Lee YK; Zang DY Acta Haematol; 2008; 120(2):108-11. PubMed ID: 18957845 [TBL] [Abstract][Full Text] [Related]
8. Pleural Effusion in Multiple Myeloma. Wang Z; Xia G; Lan L; Liu F; Wang Y; Liu B; Ding Y; Dai L; Zhang Y Intern Med; 2016; 55(4):339-45. PubMed ID: 26875957 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion. Shi XY; Yi FS; Wang Z; Qiao X; Zhai K Thorac Cancer; 2020 Feb; 11(2):320-328. PubMed ID: 31837116 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic significance of survivin levels in malignant pleural effusion. Görgün D; Seçik F; Midilli K; Akkaya V; Yıldız P Respir Med; 2013 Aug; 107(8):1260-5. PubMed ID: 23791464 [TBL] [Abstract][Full Text] [Related]
11. Predictive Factors and Treatment Outcomes of Tuberculous Pleural Effusion in Patients With Cancer and Pleural Effusion. Lee J; Lee YD; Lim JK; Lee DH; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH Am J Med Sci; 2017 Aug; 354(2):125-130. PubMed ID: 28864369 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K; Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928 [TBL] [Abstract][Full Text] [Related]
13. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723 [TBL] [Abstract][Full Text] [Related]
14. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival. Lumachi F; Mazza F; Ermani M; Chiara GB; Basso SM Anticancer Res; 2012 Nov; 32(11):5071-4. PubMed ID: 23155281 [TBL] [Abstract][Full Text] [Related]
15. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion. Chierakul N; Kanitsap A; Chaiprasert A; Viriyataveekul R Respirology; 2004 Mar; 9(1):66-9. PubMed ID: 14982604 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer patients with malignant pleural effusions. Park DS; Kim D; Hwang KE; Hwang YR; Park C; Seol CH; Cho KH; Kim BR; Park SH; Jeong ET; Kim HR Yonsei Med J; 2013 Mar; 54(2):396-402. PubMed ID: 23364973 [TBL] [Abstract][Full Text] [Related]
17. Myelomatous pleural effusion in multiple myeloma- A rare presentation. Pradeep IY; Mayuri RK; Sourabh SP; Nirali MP J Cancer Res Ther; 2024 Jan; 20(1):476-478. PubMed ID: 38554369 [TBL] [Abstract][Full Text] [Related]
18. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion. Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808 [TBL] [Abstract][Full Text] [Related]
19. Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. Nakazato T; Suzuki K; Mihara A; Sanada Y; Kakimoto T Intern Med; 2009; 48(20):1827-32. PubMed ID: 19834276 [TBL] [Abstract][Full Text] [Related]
20. Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma. Tomoda C; Ogimi Y; Saito F; Masaki C; Akaishi J; Matsuzu K; Suzuki A; Uruno T; Ohkuwa K; Shibuya H; Kitagawa W; Nagahama M; Sugino K; Ito K Endocr J; 2016; 63(3):257-61. PubMed ID: 26655349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]